Issue 158

Short Wave Pharma: innovating eating disorder care with psychedelics

Psychedelic Health speaks to Short Wave Pharma CEO Rivki Stern about the company’s plans to innovate eating disorder care through psychedelics and its recent acquisition by Psych Capital.

Short Wave Pharma was recently acquired by global investment firm Psych Capital. The companies are on a mission to transform mental health care, focusing on innovative approaches and treatments, including psychedelics, which are increasingly gaining acceptability as clinical research results accumulate.

The company’s clinical programmes are particularly focused on Anorexia nervosa – a complex mental health condition with one of the highest fatality rates. Despite the condition being associated with high rates of suicide, it is a hugely underserved area of mental health, with no FDA-approved pharmacological drug, and a high rate of chronicity.

VOLUNTEERS CALLED TO SUPPORT PSYCHEDELIC RESEARCH

Clerkenwell Health is calling for volunteers to join its groundbreaking clinical trials that will research whether psychedelics can provide effective treatments for complex mental health conditions.

The company is seeking a diverse group of volunteers from across the UK between 18 and 65 years old to take part in the trials if they suffer from a relevant condition.

MICRODOSING PSYCHEDELICS COULD HELP PEOPLE WITH ADHD

New research published in Frontiers in Psychiatry suggests that microdosing psychedelics like LSD or magic mushrooms might improve mindfulness in adults with ADHD, Vice reports.

“We found improvements in all facets of mindfulness after four weeks of microdosing,” said study author Eline C. H. M. Haijen.

BUSINESS AND INVESTMENT

Clearmind Medicine has announced receipt of a Staff Delisting Determination from the Listing Qualifications Department of the Nasdaq in accordance with Nasdaq Listing Rule 5550(a)(2).

Algernon Pharmaceuticals has signed a Letter of Intent with Seyltx to acquire Algernon’s NP-120 research programme for USD $2M cash and a 20% common share equity position in Seyltx.

Beckley Retreats has launched its Signature Program for Personal Discovery and Transformation, an 11-week curriculum of preparation and integration.

Silo Pharma has announced a license agreement with Medspray Pharma BV for its soft mist nasal spray technology, the delivery mechanism selected for Silo’s intranasal therapeutic drug SPC-15.

Would your organisation benefit from engaging Europe's psychedelic medicine community?

Partnership with Psychedelic Health provides the opportunity to engage an audience ready to support the development of psychedelic medicine.

For more information and to request the media kit, please email stephanie@psych.global

REQUEST MEDIA KIT

SCIENCE AND RESEARCH

Psilocybin shows promise for treating eating disorders, but more controlled research is needed, writes Elena Koning in The Conversation.

Forbes explores three reasons why safe psychedelic therapy might still be a distant dream.

Proponents of a new wave of interest in hallucinogens say the right trip at the right time can change how people think about the natural world, writes Bloomberg.

Applied Clinical Trials looks at how to break historic barriers to ensure psychedelic therapy’s future.

REGULATION AND LEGISLATION

A group of medical and health practitioners is calling for a comprehensive review of the current rules, regulations and guidelines for the use of psychedelic-assisted therapy in Australia, writes Hospital and Healthcare.

Eisenkraft Klein explores why turning a blind eye to psychedelic drugs is the wrong approach for The London Free Press, focusing on developments in Canada, and proposing a better way forward.

ARTICLES OF INTEREST

A million fewer people are gaining health benefits from nature since the COVID-19 pandemic.

Even after receiving a diagnosis, many children and adolescents do not receive mental health treatment.